Carlsmed – an AI-driven personalized surgery medical technology company – announced a $52.5 million Series C funding round co-led by B Capital and U.S. Venture Partners.
The proceeds from this funding round will help accelerate the commercialization of the aprevo personalized spine surgery platform for lumbar fusion procedures and the development of aprevo for cervical fusions (launching in 2025).
Carlsmed received Breakthrough Device designation by the FDA for aprevo lumbar and cervical patient-specific interbody fusion devices. And the Carlsmed implantable devices and software platforms have been FDA cleared for lumbar spine fusion, including anterior, lateral, and transforaminal approaches.
KEY QUOTES:
“We started Carlsmed to improve patient outcomes through personalized surgery, and recent clinical publications indicate that aprevo patient specific implants are achieving this goal. Our AI-enabled technology platform and innovative business model allows us to scale production rapidly to meet growing demand and empower patients.”
– Mike Cordonnier, CEO of Carlsmed
“Carlsmed is transforming spine surgery through the application of its AI-enabled technology and has proven to be a category creator in a market overdue for meaningful innovation. Personalized surgery will be the standard of care in spine, and we look forward to supporting this transformation led by Carlsmed.”
– Dr. Robert Mittendorff, General Partner and Head of Healthcare at B Capital
